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BACKGROUND: Female sex was not included among the high bleeding risk (HBR) criteria by the Academic Research Consortium 
(ARC) as it remains unclear whether it constitutes an HBR condition after percutaneous coronary intervention. We investigated 
whether female sex associates with HBR and assessed the performance of ARC HBR criteria separately in women and men.
METHODS AND RESULTS: Among all consecutive patients undergoing percutaneous coronary intervention between 2009 and 
2018, bleeding occurrences up to 1 year were prospectively collected and centrally adjudicated. All but one of the originally 
defined ARC HBR criteria were assessed, and the ARC HBR score generated accordingly. Among 16 821 patients, 25.6% 
were women. Compared with men, women were older and had lower creatinine clearance and hemoglobin values. After ad-
justment, female sex was independently associated with access- site (adjusted hazard ratio, 2.14; 95% CI, 1.22– 3.74; P=0.008) 
but not with overall or non– access- site 1- year Bleeding Academic Research Consortium 3 or 5 bleeding. This association 
remained consistent when the femoral but not the radial approach was chosen. The ARC HBR score discrimination, using 
the original criteria, was lower among women than men (c- index 0.644 versus 0.688; P=0.048), whereas a revised ARC HBR 
score, in which age, creatinine clearance, and hemoglobin were modeled as continuous rather than dichotomized variables, 
performed similarly in both sexes.
CONCLUSIONS: Female sex is an independent predictor for access- site bleeding but not for overall bleeding events at 1 year 
after percutaneous coronary intervention. The ARC HBR framework shows an overall good performance in both sexes, yet 
is lower in women than men, attributable to dichotomization of age, creatinine clearance, and hemoglobin values, which are 
differently distributed between sexes.
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Bleeding events after percutaneous coronary in-tervention (PCI) are associated with worse out-comes.1 As a result, the appropriate identification 
and management of high bleeding risk factors is rec-
ommended for all patients undergoing PCI.
Among the clinical factors predisposing to a height-
ened bleeding risk, the role of sex remains unclear. 
Evidence suggests that female sex per se confers higher 
bleeding risks, as it relates to in- hospital2,3 and/or over-
all occurrences.4,5 On the other hand, several studies 
did not find a similar association.6– 8 International rec-
ommendations on duration of dual antiplatelet therapy 
reflect this uncertainty, with female sex being included 
among the bleeding risk factors in the American9 but 
not the European guidelines.10 Similarly, female sex ac-
crues the predicted hemorrhagic hazard among some 
risk scores11,12 but not in others.13,14
The Academic Research Consortium (ARC) for high 
bleeding risk (HBR) has recently proposed by consen-
sus a set of clinical and biochemical criteria, among 
which sex is not included, for the identification of pa-
tients with HBR.15 The discriminatory performance 
of these criteria, as originally described without ad-
aptations, was recently assessed,16 but no indepen-
dent assessment of this new framework in men and 
women exists. Inappropriate estimation of the bleeding 
risk could lead to erroneous therapeutic management 
among female patients only on the basis of sex.17
We sought therefore to investigate, in a large co-
hort of consecutive patients undergoing PCI, whether 
female sex is independently associated with higher 
bleeding occurrences and whether the recent ARC 
HBR criteria and definitions provide a consistent risk 
stratification tool in both men and women.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
All consecutive patients undergoing PCI at Bern 
University Hospital, Switzerland, between February 2009 
and December 2018 were prospectively entered into the 
Bern PCI Registry (Clini calTr ials.gov: NCT02241291), 
which complies with the Declaration of Helsinki and was 
approved by the institutional ethics committee. All pa-
tients providing informed consent were included with-
out formal exclusion criteria. Demographic, clinical, and 
procedural characteristics; laboratory values; hospital 
outcomes; and bleeding and ischemic events occur-
ring up to 1 year after PCI were prospectively collected. 
The fulfillment of all but one (planned surgery) ARC HBR 
criteria were systematically screened for each patient 
according to the originally proposed definitions without 
adaptations (Table S1). We excluded patients for whom 
≥1 ARC HBR criteria could not be assessed because of 
missing information (except for planned surgery).
Clinical End Points
The primary end point was the composite of Bleeding 
Academic Research Consortium (BARC) type 3 or 5, 
further stratified into non– access- site and access- 
site related. Secondary end points included BARC 2, 
3 or 5 bleeding and according to the Thrombolysis 
in Myocardial Infarction and Global Strategies for 
Opening Occluded Coronary Arteries scales. Ischemic 




• Female sex per se was associated with greater 
access- site bleeding, especially from the femo-
ral artery, but not with overall or non- access site 
type 3 or 5 occurrences at 1 year, according 
to Bleeding Academic Research Consortium 
classification.
• The Academic Research Consortium high 
bleeding risk framework appears to be a suit-
able risk stratification tool for bleeding risk as-
sessment in both sexes, provided women are 
considered at high bleeding risk for access- site 
events irrespective of high bleeding risk criteria 
and age, and creatinine clearance and hemo-
globin are counted as continuous instead as 
dichotomous variables.
What Are the Clinical Implications?
• Strategies aiming at mitigating access- site 
bleeding risk among women, irrespective of 
high bleeding risk status and including radial 
access- site selection, should be adopted.
• The overall and non– access- site bleeding risk 
after percutaneous coronary intervention should 
not be assessed on the basis of sex but on the 
other validated bleeding predictors included in 
the Academic Research Consortium high bleed-
ing risk criteria, which need be assessed in a 
continuous rather than dichotomized fashion.
Nonstandard Abbreviations and Acronyms
adjHR adjusted hazard ratio
ARC Academic Research Consortium
BARC Bleeding Academic Research 
Consortium
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Further details about methods can be found in 
Data S1.
Statistical Analysis
Baseline and procedural characteristics and medica-
tions are shown as means and SDs or counts with 
percentages; P values for comparisons of women 
versus men were obtained for continuous variables 
using t tests, for categorical variables using Fisher’s 
tests (2×2 comparisons) or chi- square tests. Time- to- 
event analyses and Kaplan- Meier cumulative event 
curves were used for clinical outcomes. Univariable 
and multivariable Weibull time- to- event analyses were 
used to assess the association of sex and other clinical 
characteristics with the bleeding outcomes specified 
above. Multiple imputation of missing risk factors (other 
than ARC HBR criteria) was performed. The 20 gener-
ated data sets were used to derive predictors of BARC 
3 or 5 bleeding and estimates were combined using 
Rubin’s rule. Predictors with a P value below 0.2 were 
retained in the final models. Models were robustified by 
year of PCI. Unadjusted and adjusted rates of BARC 
3 or 5 were additionally calculated after stratification 
of women and men by vascular access. Interaction 
effects between female sex and each adjusted ARC 
HBR criterion to predict BARC 3 or 5 bleeding was 
estimated.
Harrell’s c- index (concordance statistic) was cal-
culated to assess whether the ARC HBR score pre-
dicted BARC 3 or 5 bleeding in the overall population, 
as well as in women and men separately. The ARC 
HBR criteria age, hemoglobin, and estimated glomeru-
lar filtration rate using creatinine (estimated glomerular 
filtration rate) were also fitted as continuous risk factors 
to explore whether some differences between women 
and men might be attributable to dichotomization of 
these risk factors.
Analyses were done in Stata Release 16.1 
(StataCorp LP, College Station, TX).
RESULTS
Population Characteristics
Between February 2009 and December 2018, 17 339 
consecutive patients were included in the Bern PCI 
Registry. After excluding 518 patients with incomplete 
hemoglobin (n=459) or creatinine (n=59) data, the final 
study population comprised 16 821 patients. Follow- up 
was complete in 15  708 of 16  821 patients (93.4%); 
for 531 (3.1%) only information about vital status was 
available, and 582 (3.5%) were lost to follow- up. In the 
final study population, mean age was 67.9 years, 4307 
(25.6%) were women, 9503 (56.5%) presented with 
acute coronary syndrome, and 16.9% had a Killip class 
>1 at presentation (Table 1).
Compared with men, female patients were on av-
erage 6 years older (72.1±11.4 versus 66.4±11.8 years); 
had a lower body mass index and hemoglobin val-
ues; were more likely to suffer from hypertension, di-
abetes mellitus, chronic kidney disease (CKD), and 
malignancy; and were more likely to have a non– ST- 
segment– elevation acute coronary syndrome as well 
as acute heart failure at presentation. Men were more 
frequently smokers and more frequently had a history 
of coronary disease and chronic obstructive lung dis-
ease (Table  1). Femoral access was more frequently 
used among women than men (70.4% versus 65.3%; 
P<0.001). Women had a lower number of treated 
coronary lesions, better Thrombolysis in Myocardial 
Infarction flow before PCI (Thrombolysis in Myocardial 
Infarction flow 0– 1: 21.3% versus 24.1%) and fewer 
high- risk features such as in- stent restenosis, throm-
botic lesions, or chronic total occlusion (Table  S2). 
Other procedural and discharge medications are avail-
able in Table S3.
Clinical Outcomes
At 1- year follow- up, 217 (5.5%) overall BARC 3 or 5 
bleeding events occurred among women, of which 
176 (4.5%) were unrelated and 44 (1.1%) were related 
to the access site; among men, the corresponding 
occurrences attained at 458 (4.0%), 417 (3.6%), and 
47 (0.4%), respectively. Women as compared with 
men had an increased unadjusted risk of overall 
(hazard ratio [HR], 1.41; 95% CI, 1.20– 1.66; P<0.001), 
non– access- site (HR, 1.25; 95% CI, 1.05– 1.49; 
P=0.013) and access- site (HR, 2.76; 95% CI, 1.83– 
4.16; P<0.001) BARC 3 or 5 bleeding (Table 2). Crude 
event rates of BARC 2, intracranial or coronary artery 
bypass grafting– related bleeding did not differ be-
tween sexes (Table S4). The results remained largely 
consistent when the Global Strategies for Opening 
Occluded Coronary Arteries and Thrombolysis in 
Myocardial Infarction bleeding scales were appraised 
(Table  S4). Other factors associated with BARC 3 
or 5 bleeding at unadjusted analyses are shown in 
Table  S5. Mortality and ischemic outcomes are re-
ported in Table 2.
At multivariate analysis, after adjusting for baseline, 
procedural, and treatment imbalances, female sex was 
no longer associated with higher risk of overall (ad-
justed hazard ratio [adjHR], 1.01; 95% CI, 0.81– 1.27; 
P=0.918) or non– access- site (adjHR, 0.89; 95% CI, 
0.73– 1.07; P=0.244) BARC 3 or 5 bleeding. However, 
access- site– related BARC 3 or 5 events remained 
2- fold higher among women compared with men 
(adjHR, 2.14; 95% CI, 1.22– 3.74; P=0.008) (Figure 1A 
and Table S6). When the composite of BARC 2, 3, or 
5 bleeding was appraised, female sex remained asso-
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1.34– 3.43; P=0.001) but not with overall occurrences 
(adjHR, 0.89; 95% CI, 0.74– 1.06; P=0.195), and even 
appeared protective toward non– access- site (adjHR, 
0.78; 95% CI, 0.65– 0.94; P=0.008) events (Figure 1A 
and Tables S7 and S8).
Bleeding Outcomes Stratified by Access 
Site
Among patients in whom the femoral access was 
used, the crude rate of 1- year BARC 3 or 5 bleeding 
in women and men reached 7.3% and 5.1% for over-
all, 6.2% and 4.7% for non– access- site, and 1.3% 
and 0.5% for access- site occurrences, conferring to 
women as compared with men an increased unad-
justed risk of overall, non– access- site and access- site 
1- year BARC 3 or 5 bleeding (Figure S1A). Conversely, 
when the radial approach was chosen, there were no 
differences between women and men for overall (crude 
rate 4.3% versus 4.4%), non– access- site (3.8% versus 
4.1%) or access- site (0.5% versus 0.3%) 1- year BARC 
3 or 5 bleeding events (Figure S1B).
At adjusted analysis, when the femoral access was 
attempted, female sex conferred an increased risk of 
access- site bleeding very close to statistical significance 
(adjHR, 1.99; 95% CI, 0.96– 4.11; P=0.063) but not of 
overall and non– access- site bleeding (Figure S1A). By 
choosing the radial approach, female sex did not asso-
ciate with a higher risk of access- site bleeding compli-
cations (adjHR, 1.12; 95% CI, 0.43– 2.96; P=0.811) and 
resulted even protective in regard to overall and non– 
access- site occurrences (Figure S1B). These results re-
mained consistent when also BARC 2 bleeding events 
were taken into account (Figure S1A and S1B).
Table 1. Baseline Characteristics According to Sex
All Patients (N=16 821) Men (n=12 514) Women (n=4307) P Value
Age, y n=16 821, 67.9±12.0 n=12 514, 66.4±11.8 n=4307, 72.1±11.4 <0.001
BMI, kg/m2 n=16 182, 27.4±4.7 n=12 066, 27.5±4.4 n=4116, 26.9±5.5 <0.001
Current smoker n=16 575, 4488 (27.1) n=12 335, 3609 (29.3) n=4240, 879 (20.7) <0.001
Hypertension n=16 694, 11 577 (69.3) n=12 416, 8330 (67.1) n=4278, 3247 (75.9) <0.001
Diabetes mellitus n=16 757, 3893 (23.2) n=12 464, 2837 (22.8) n=4293, 1056 (24.6) 0.014
Hypercholesterolemia n=16 665, 10 741 (64.5) n=12 393, 8028 (64.8) n=4272, 2713 (63.5) 0.138
Family history of coronary artery 
disease
n=16 684, 4323 (25.9) n=12 404, 3159 (25.5) n=4280, 1164 (27.2) 0.027
Previous myocardial infarction n=16 743, 2976 (17.8) n=12 453, 2425 (19.5) n=4290, 551 (12.8) <0.001
Previous PCI n=16 741, 3989 (23.8) n=12 449, 3168 (25.4) n=4292, 821 (19.1) <0.001
Previous CABG n=16 759, 1701 (10.1) n=12 463, 1435 (11.5) n=4296, 266 (6.2) <0.001
Previous TIA or stroke n=16 750, 1237 (7.4) n=12 456, 914 (7.3) n=4294, 323 (7.5) 0.685
Peripheral arterial disease n=16 738, 1448 (8.7) n=12 448, 1064 (8.5) n=4290, 384 (9.0) 0.413
History of malignancy n=16 746, 1810 (10.8) n=12 455, 1303 (10.5) n=4291, 507 (11.8) 0.014
Renal failure* n=16 098, 3329 (20.7) n=12 008, 2074 (17.3) n=4090, 1255 (30.7) <0.001
History of atrial fibrillation/atrial 
flutter
n=11 845, 1450 (12.2) n=8810, 1055 (12.0) n=3035, 395 (13.0) 0.131
Chronic obstructive lung disease n=16 747, 1113 (6.6) n=12 455, 887 (7.1) n=4292, 226 (5.3) <0.001
History of spontaneous bleeding n=16 819, 729 (4.3) n=12 513, 539 (4.3) n=4306, 190 (4.4) 0.762
History of gastrointestinal bleeding n=16 744, 368 (2.2) n=12 452, 274 (2.2) n=4292, 94 (2.2) 1.000
Left ventricular function (%) n=15 122, 52.3±13.7 n=11 261, 51.9±13.5 n=3861, 53.5±14.0 <0.001
Hemoglobin before PCI, g/L n=14 853, 136.54±18.11 n=11 059, 139.82±17.49 n=3794, 127.00±16.44 <0.001
Hemoglobin nadir, g/L n=14 003, 126.97±20.64 n=10 358, 130.42±20.04 n=3645, 117.16±19.10 <0.001
ARC HBR score n=16 821, 0.66±0.83 n=12 514, 0.60±0.80 n=4307, 0.82±0.86 <0.001
Clinical indication for PCI n=16 821 n=12 514 n=4307 <0.001
Stable CAD 7318 (43.5) 5426 (43.4) 1892 (43.9) 0.521
Unstable angina 783 (4.7) 576 (4.6) 207 (4.8) 0.586
NSTEMI 4218 (25.1) 3056 (24.4) 1162 (27.0) 0.001
STEMI 4502 (26.8) 3456 (27.6) 1046 (24.3) <0.001
Killip class II, III or IV n=16 780, 2844 (16.9) n=12 486, 2042 (16.4) n=4294, 802 (18.7) <0.001
Data are presented as absolute numbers and percentage or mean±SD. ARC indicates Academic Research Consortium; BMI, body mass index; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; HBR, high bleeding risk; NSTEMI, non– ST- segment– elevation myocardial infarction; PCI, 
percutaneous coronary intervention; STEMI, ST- segment– elevation myocardial infarction; and TIA, transient ischemic attack.
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ARC HBR Criteria Stratified by Sex
Forty- three percent of women and 32% of men quali-
fied as HBR, defined by the presence of at least 2 minor 
or 1 major ARC HBR criterion. Advanced age, CKD, 
anemia, and use of nonsteroidal anti- inflammatory 
drugs or corticosteroids were more common among 
women, while a history of active malignancy was more 
frequent among men (Figure S2A). The remaining ARC 
HBR criteria were similarly distributed between sexes. 
The unadjusted risks of BARC 3 or 5 bleeding for each 
ARC HBR criterion among men or women are shown 
in Figure S3. At multivariable analysis, in which each 
ARC HBR criterion was adjusted for all major or minor 
criteria but the one considered, no significant interac-
tion was found between sex and each criterion in the 
likelihood of BARC 3 or 5 bleeding, except for CKD (P 
interaction for sex=0.035) (Figure  2). When age, cre-
atinine clearance, and hemoglobin were entered into 
the model as continuous rather than dichotomized 
variables, as suggested by the ARC HBR, interaction 
testing between sex and ARC HBR criteria became 
consistently negative (Figure 3A).
ARC HBR Score Stratified by Sex
The ARC HBR score was higher among women than 
men (0.82±0.86 versus 0.60±0.80; P<0.001) and dif-
ferently distributed in the 2 groups (Figure S2B). For 
each 0.5- point increase of the ARC HBR score from 
0 to ≥2.5, there was a stepwise increase of BARC 
3 or 5 bleeding rates at 1 year in both groups, with 
event rates increasing from 2.89% to 14.16% among 
women and from 1.77% to 12.92% among men. The 
incidence of BARC 3 or 5 bleeding was similar in 
the 2 sexes for each point of the score ≥1. For score 
values <1, women showed a significantly higher 
bleeding risk compared with men (Figure 1B), mainly 
attributable to an excess of access- site occurrences 
(Figure S4).
The ARC HBR score discrimination, in terms of 
Harrell’s c- index with respect to BARC 3 or 5 bleeding, 
was lower among women compared with men (0.644; 
95% CI, 0.607– 0.680 versus 0.688; 95% CI, 0.664– 
0.712; P=0.048) (Figure 1C). When age, creatinine clear-
ance, and hemoglobin were entered into the model 
as continuous rather than dichotomized variables, as 
Table 2. Bleeding and Ischemic Events at 1 Year According to Sex
Men (n=12 514) Women (n=4307) Hazard Ratio (95% CI) P Value
Bleeding BARC 3 or 5 458 (4.0) 217 (5.5) 1.41 (1.20– 1.66) <0.001
Access site 47 (0.4) 44 (1.1) 2.76 (1.83– 4.16) <0.001
Non– access site 417 (3.6) 176 (4.5) 1.25 (1.05– 1.49) 0.013
Bleeding BARC 2, 3, or 5 724 (6.3) 296 (7.5) 1.22 (1.06– 1.39) 0.005
Access site 53 (0.4) 51 (1.2) 2.83 (1.93– 4.16) <0.001
Non– access site 681 (5.9) 249 (6.4) 1.08 (0.94– 1.25) 0.288
Death 855 (7.2) 340 (8.4) 1.17 (1.04– 1.33) 0.012
Cardiac death 601 (5.1) 244 (6.1) 1.20 (1.03– 1.39) 0.018
Vascular (noncardiac) death 59 (0.5) 30 (0.8) 1.50 (0.97– 2.33) 0.070
Noncardiovascular death 195 (1.7) 66 (1.7) 1.00 (0.76– 1.33) 0.977
Myocardial infarction 514 (4.4) 187 (4.7) 1.07 (0.91– 1.27) 0.413
Target vessel myocardial 
infarction
377 (3.2) 142 (3.5) 1.11 (0.91– 1.34) 0.296
Revascularization (any) 900 (8.0) 292 (7.6) 0.96 (0.84– 1.09) 0.522
Target lesion revascularization 462 (4.1) 156 (4.1) 1.00 (0.83– 1.20) 0.981
Target vessel 
revascularization
663 (5.9) 213 (5.5) 0.95 (0.81– 1.11) 0.505
Definite stent thrombosis 153 (1.3) 42 (1.0) 0.81 (0.57– 1.13) 0.215
CVE (stroke and TIA) 221 (1.9) 82 (2.1) 1.10 (0.85– 1.41) 0.479
Stroke (any) 178 (1.6) 70 (1.8) 1.16 (0.88– 1.53) 0.288
Stroke (ischemic stroke) 135 (1.2) 47 (1.2) 1.03 (0.74– 1.43) 0.875
Stroke (intracerebral 
hemorrhage)
38 (0.3) 21 (0.6) 1.64 (0.96– 2.79) 0.070
Stroke (unclear etiology) 5 (0.0) 2 (0.1) 1.18 (0.23– 6.08) 0.844
TIA 44 (0.4) 12 (0.3) 0.80 (0.42– 1.52) 0.504
NACCE 1662 (13.9) 675 (16.5) 1.21 (1.11– 1.32) <0.001
Data are presented as absolute numbers and percentage (%). BARC indicates Bleeding Academic Research Consortium; CVE, cerebrovascular event; 
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Figure 1. BARC 3 or 5 bleeding at 1 year and ARC HBR criteria in female (F) vs male patients (M).
Adjusted (Adj) hazard ratio for overall, non– access- site and access- site bleeding (A). ARC HBR 
criteria modeled as a score (1 point for major criterion, 0.5 for minor): bleeding incidence for score 
values from 0 to ≥2.5 (B) and score discrimination using Harrell’s c- index (C). The dotted line 
indicates a 4% incidence of bleeding, expected in presence of a major ARC HBR criterion (definition 
in Table S1). ARC indicates Academic Research Consortium; BARC, Bleeding Academic Research 
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suggested by the ARC HBR, the ARC HBR score dis-
crimination significantly improved among female pa-
tients to the extent that it no longer differed between 
sexes (Figure 3B).
DISCUSSION
We aimed at addressing the conundrum between 
bleeding risk and female sex in patients undergoing 
PCI and ascertained whether the ARC HBR definition 
performs consistently across both sexes in a pro-
spective all- comer cohort of 16 821 consecutive pa-
tients undergoing PCI, who underwent central event 
adjudication.
Our findings can be summarized as follows:
1. Female patients had higher crude risk of BARC 3 
or 5 bleeding at 1  year compared with male pa-
tients; after adjustment, female sex per se remained 
independently associated with access- site– related 
Figure 2. Adjusted (Adj) incidence of BARC 3 or 5 bleedings at 1 year for minor and major (*) ARC HBR criteria in male (M) 
and female patients (F).
Interaction between sex and each ARC HBR criterion is reported (P interaction [int] with sex). The dotted line indicates a 4% incidence 
of bleeding, expected in presence of a major ARC HBR criterion (definition in Table S1). ARC indicates Academic Research Consortium; 
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Figure 3. Modified ARC HBR criteria and BARC 3 or 5 bleedings at 1 year.
Modified ARC HBR criteria (age, creatinine clearance, and hemoglobin analyzed as continuous variables) to predict BARC 3 or 5 
bleedings at 1 year in males (M) and females (F): adjusted (Adj) bleeding incidence for minor and major (*) ARC- HBR criteria (A) and 
score discrimination using Harrell’s c- index (B). Bold risk factors: cumulative incidence calculated for the mean of that risk factor. 
The dotted line indicates a 4% incidence of bleeding, expected in presence of a major ARC HBR criterion (definition in Table S1). 
ARC indicates Academic Research Consortium; BARC, Bleeding Academic Research Consortium; eGFR, glomerular filtration rate 
according to Modification of Diet in Renal Disease formula; HBR, high bleeding risk; int, interaction; and PCI, percutaneous coronary 
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but not overall or non– access- site– related BARC 
3 or 5 bleeding.
2. These results remained consistent when consider-
ing only patients in whom the femoral access was 
used, while there was no unadjusted and adjusted 
sex differences in terms of bleeding (overall, not re-
lated and related to access site) when the radial ap-
proach was chosen.
3. Compared with men, women were more likely to 
qualify as HBR according to the ARC HBR criteria 
and presented higher ARC HBR scores, mainly at-
tributable to more frequent fulfillment of advanced 
age, CKD, or anemia criteria.
4. In a multivariate adjusted model, among the ARC 
HBR criteria, CKD showed a significant interaction 
with sex, suggesting higher risk of BARC 3 or 5 
bleeding among women than men.
5. The performance of the ARC HBR score in terms of 
bleeding risk discrimination showed an overall good 
performance in both sexes, yet lower in women than 
men.
6. When age, hemoglobin, and creatinine clearance 
were forced into the model as continuous rather than 
dichotomized variables, interaction testing with sex 
was no longer significant, and the ARC HBR score 
performed consistently across sexes.
Women have an apparent biological protection from 
coronary artery disease, which translates to a decade- 
long delay in the onset of coronary artery disease and 
a different presentation profile and comorbid burden 
as compared with men. It remains unclear whether 
female sex per se affects the bleeding risk after PCI. 
Our analysis addresses this important knowledge gap 
by showing that after extensive adjustments for several 
characteristics that differ between women and men, 
like age, prevalence of CKD or anemia, female sex does 
not confer a higher risk of overall or non– access- site 
major bleeding events at 1 year, but remains associ-
ated with higher prevalence of major access- site com-
plications, especially if the femoral access was used. 
These findings are consistent with previous studies, 
showing that use of radial access reduces significantly 
the rate of bleeding in both sexes,20– 23 with a possible 
greater benefit among women.21,22
A smaller reference diameter of the common fem-
oral artery have been investigated as possible cause 
of increased predisposition to access- site bleed-
ing in women in whom the femoral approach was 
chosen.24
Moreover, we observed that when any actionable 
bleeding events were appraised (ie, BARC 2, 3, or 5), 
female sex emerged as a protective factor for non– 
access- site– related occurrences, consistent with prior 
findings.25,26
In 8 of 20 contemporary studies reporting an ad-
justed sex- related risk of bleeding at >6 months after 
PCI (Table S9), female sex emerged as an indepen-
dent predictor of bleeding. Yet a sensitivity analysis 
excluding periprocedural bleeding was performed in 
only 1 study,4 which demonstrated that female sex 
was no longer a predictor of bleeding at 1 year when 
only postdischarge major bleeding was appraised. 
Furthermore, in 2 other studies,27,28 the increased 
bleeding risk among female patients was largely 
driven by nonactionable occurrences (BARC 1), and 
in some other studies,29 the low number of bleeding 
events may have hampered extensive multivariable 
adjustments.
Our results are supported by the observation that 
female sex appears in scores conceived to predict in- 
hospital or short- term bleedings (ie, ACUITY [Acute 
Catheterization and Urgent Intervention Triage Strategy]11 
or CRUSADE [Can Rapid Risk Stratification of Unstable 
Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA Guidelines] score12), but 
not across scores developed to predict only spontaneous 
(eg, PRECISE- DAPT [Predicting Bleeding Complications in 
Patients Undergoing Stent Implantation and Subsequent 
Dual AntiPlatelet Therapy]14) or long- term bleeding occur-
rences (eg, PARIS [Patterns of Non- Adherence to Anti- 
Platelet Regimen in Stented Patients]13).
The recently proposed ARC HBR states that sex 
differences in bleeding risk should be considered in 
trial design and the interpretation of study outcomes 
but did not include female sex among risk factors for 
HBR.15 No study has so far assessed this new frame-
work separately in both male and female patients. Our 
analysis supports the ARC consensus decision not to 
include sex as an independent criterion for HBR and 
suggests that this novel HBR definition allows a good 
prediction of bleeding risk in both sexes. Nevertheless, 
we observed a lower performance of ARC HBR score 
among female as compared with male patients attrib-
utable to increased age and lower creatinine clearance 
and hemoglobin values among women. A revised HBR 
model, in which age, renal function, and hemoglobin 
values are analyzed as continuous instead of dichot-
omous variables, provides a more consistent bleeding 
risk prediction in both sexes.
Our results support the adoption of strategies 
aiming at mitigating access- site bleeding risk among 
women, irrespective of HBR status, including radial 
access- site selection.21
Strengths and Limitations
To our knowledge, this is the first study assessing the 
risk of bleeding at 1  year in female versus male pa-
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criteria without adaptations. Our results have several 
limitations. First, they arise from a single- center al-
beit large cohort study and, as such, may suffer from 
limited generalizability. Yet the distribution of baseline 
characteristics between sexes as well as the incidence 
of bleeding and ischemic outcomes are consistent 
with those of previous multicenter cohorts.3– 5 Eight 
ARC HBR criteria were retrospectively adjudicated, 
which may have led to imprecision and underestima-
tion of their true prevalence in our PCI population, but 
it is reassuring that after independent readjudication of 
ARC HBR criteria by a different observer in a random 
sample of 597 patients, the agreement with the first 
observer attained 98%.
The ARC HBR criteria were not originally conceived 
as a point- based score. Nevertheless, the creation of 
an ARC HBR score allowed a more precise bleeding 
risk stratification.
Finally, a single major ARC HBR criterion, namely, 
nondeferrable major surgery was not assessed.
CONCLUSIONS
Female sex after PCI is an independent risk factor for 
access- site but not for overall or non– access- site– 
related (ie, spontaneous) bleeding at 1 year when the 
femoral approach is adopted. The ARC HBR frame-
work shows a slightly lower discrimination performance 
in female as compared with male patients but appears 
a suitable risk stratification tool for bleeding risk as-
sessment in both sexes, provided female patients are 
considered at HBR for access- site events, and greater 
age and lower creatinine clearance and hemoglobin 
values are accounted for.
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Data collection during follow-up 
Throughout 1 year, patients were systematically contacted after discharge in case of any unscheduled 
hospital visit due to bleeding or ischemic complications (death, myocardial infarction, stroke) in order 
to collect details about the event and concomitant medical treatment; they were contacted as well in 
case of staged procedure. At 1 year after index PCI all living patients received a form containing 
questions about adverse events, including bleeding occurrences, and in case of missing response they 
were contacted by telephone. General practitioners, referring cardiologists and other medical 
institutions were reached as necessary in order to collect discharge letters, coronary angiography 
documentation or any other relevant medical records, which were reviewed and used to adjudicate the 
events.  
Survival data were obtained from hospital records and municipal civil registries. 
 
DAPT Duration 
The prescription of DAPT after PCI, consisting of acetylsalicylic acid and a P2Y12 inhibitor, followed 
the recommendations of international guidelines. Dual antiplatelet therapy (DAPT) consisting of 
acetylsalicylic acid and a P2Y12 inhibitor was initiated before, at the time, or immediately after the 
procedure. Prasugrel was introduced as of September 2009, and ticagrelor as of November 2011. The 
majority of patients with chronic coronary syndrome received clopidogrel. The routinely recommended 
DAPT duration was 12 months for all acute or chronic coronary syndrome patients until August 2017, 
unless high bleeding risk features were deemed present, including concomitant oral anticoagulation, 
which mandated DAPT not to exceed a duration of 6 months. From August 2017, the routinely 
recommended DAPT duration for chronic coronary syndrome patients became 6 months, in agreement 
with existing European and American guidelines. 
 
Clinical endpoints 
All bleeding, ischemic and fatal events were adjudicated against original source documents by one 
trained physician and verification was carried out by a second one; disagreements were resolved 
through a third part adjudication. 








- BARC Type 2: any overt, actionable sign of hemorrhage (eg, more bleeding than would be 
expected for a clinical circumstance, including bleeding found by imaging alone) that does not 
fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) 
requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to 
hospitalization or increased level of care, or (3) prompting evaluation  
- BARC Type 3a: Overt bleeding plus hemoglobin drop of 3 to <5 g/dL* (provided hemoglobin 
drop is related to bleed) or any transfusion with overt bleeding  
- BARC Type 3b: Overt bleeding plus hemoglobin drop ≥5 g/dL* (provided hemoglobin drop is 
related to bleed) or cardiac tamponade or bleeding requiring surgical intervention for control 
(excluding dental/nasal/skin/hemorrhoid) or bleeding requiring intravenous vasoactive agents  
- BARC Type 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic 
transformation, does include intraspinal) or subcategories confirmed by autopsy or imaging or 
lumbar puncture or intraocular bleed compromising vision 
- BARC Type 4 (CABG-related bleeding): Perioperative intracranial bleeding within 48 h or 
reoperation after closure of sternotomy for the purpose of controlling bleeding or transfusion of 
≥5 U whole blood or packed red blood cells within a 48-h period or chest tube output ≥2L 
within a 24-h period  
- BARC Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically 
suspicious  










Table S1. Definition of High bleeding risk (HBR) criteria according to academic research consortium (ARC) consensus. 
 Major Minor 
   
Advanced age   Age ≥75 years 
Oral anticoagulation Anticipated use of long-term oral anticoagulation   
Chronic kidney disease 
(CKD) 
Severe or end-stage CKD (eGFR <30 mL/min) Moderate CKD (eGFR 30–59 mL/ min) 
Anaemia Hemoglobin <11 g/dL  11–12.9 g/dL for men  
   11–11.9 g/dL for women 
Prior bleeding Spontaneous bleeding requiring hospitalization or transfusion in the past 
6 months or at any time, if recurrent 
 Spontaneous bleeding requiring hospitalization or transfusion within 
the past 12 months not meeting the major criterion 





Inherited or acquired conditions known to be associated with increased 
bleeding risk such as platelet dysfunction, von Willebrand disease, 
inherited or acquired clotting factor deficiencies (including factors VII, 
VIII [hemophilia A], IX [hemophilia B], and XI), or acquired antibodies 
to clotting factors, among others 
  
Liver cirrhosis Liver cirrhosis with portal hypertension   
NSAIDs or steroids   Long-term use of oral NSAIDs or steroids 
Active malignancy Diagnosis within the previous 12 months or ongoing active treatment, 
excluding non-melanoma skin cancer 
  
Prior stroke Previous spontaneous ICH (at any time) 
Previous traumatic ICH within the past 12 months 
Presence of a brain arteriovenous malformation 
Moderate or severe ischemic stroke within the past 6 months 
Any ischemic stroke at any time not meeting the major criterion 
Planned surgery Nondeferrable major surgery on dual antiplatelet therapy   
Prior surgery or trauma Recent major surgery or major trauma within 30 days before PCI   
 
CKD= chronic kidney disease; eGFR= glomerular filtration rate according to MDRD formula; ICH= intracranial haemorrhage; PCI= percutaneous coronary 
intervention; NSAIDs= nonsteroidal anti-inflammatory drugs;  









Table S2. Procedural characteristics in male and female patients. 
 All patients Male Female p-value 
  N = 16821 N = 12514 N = 4307   
Access site n = 11879, n =  8833, n = 3046, <0.001 
radial 3964 (33.4%) 3065 (34.7%) 899 (29.5%) <0.001 
femoral 7912 (66.6%) 5767 (65.3%) 2145 (70.4%) <0.001 
brachial 3 (0.0%) 1 (0.0%) 2 (0.1%) 0.164 
Coronary arteries treated         
Left main artery n = 16821, 809  (4.8%) n = 12514, 622  (5.0%) n = 4307,  187  (4.3%) 0.099 
Left anterior descending artery n = 16821, 8677 (51.6%) n = 12514, 6298 (50.3%) n = 4307, 2379 (55.2%) <0.001 
Left circumflex artery n = 16821, 5354 (31.8%) n = 12514, 4119 (32.9%) n = 4307, 1235 (28.7%) <0.001 
Right coronary artery n = 16821, 6104 (36.3%) n = 12514, 4514 (36.1%) n = 4307, 1590 (36.9%) 0.321 
Bypass graft n = 16821,  556  (3.3%) n = 12514,  487  (3.9%) n = 4307,   69  (1.6%) <0.001 
Number of lesions n = 16821, n = 12514, n = 4307, <0.001 
1 9767 (58.1%) 7135 (57.0%) 2632 (61.1%) <0.001 
2 4702 (28.0%) 3559 (28.4%) 1143 (26.5%) 0.016 
≥3 2352 (14.0%) 1820 (14.5%) 532 (12.4%) <0.001 
Multivessel treatment (2-3 vessels) n = 16821, 4398 (26.1%) n = 12514, 3307 (26.4%) n = 4307, 1091 (25.3%) 0.159 
IABP (prior or during PCI) n = 16813,  210  (1.2%) n = 12507,  152  (1.2%) n = 4306,   58  (1.3%) 0.524 
Percutaneous left ventricular assist device n = 15448,  128  (0.8%) n = 11489,   99  (0.9%) n = 3959,   29  (0.7%) 0.478 
Staged PCI performed n = 16821, 2714 (16.1%) n = 12514, 2120 (16.9%) n = 4307,  594 (13.8%) <0.001 
Access site of first Staged PCI n =  2147, n =  1682, n =  465, 0.089 
radial 975 (45.4%) 780 (46.4%) 195 (41.9%) 0.092 
femoral 1172 (54.6%) 902 (53.6%) 270 (58.1%) 0.092 
Nr of lesions treated N = 27085 N = 20370 N = 6715   
Lesion type         
Restenotic lesion n = 27051,  1576  (5.8%) n = 20341,  1268  (6.2%) n = 6710,   308  (4.6%) <0.001 
Evidence of thrombus n = 26980,  3883 (14.4%) n = 20293,  3065 (15.1%) n = 6687,   818 (12.2%) <0.001 
Chronic total occlusion n = 27085,   830  (3.1%) n = 20370,   661  (3.2%) n = 6715,   169  (2.5%) 0.005 
Stenting         








Any Bare-metal stent n = 25096,  1064  (4.2%) n = 18802,   802  (4.3%) n = 6294,   262  (4.2%) 0.793 
Any Absorbable scaffold* n = 25096,    79  (0.3%) n = 18802,    54  (0.3%) n = 6294,    25  (0.4%) 0.200 
Mix of types of stents n = 27085,    42  (0.2%) n = 20370,    31  (0.2%) n = 6715,    11  (0.2%) 0.834 
Only DES stents used per patient n = 27085, 24959 (92.2%) n = 20370, 18755 (92.1%) n = 6715,  6204 (92.4%) 0.400 
Total number of stents implanted in this lesion n = 25096,   1.32 ±  0.61 n = 18802,   1.32 ±  0.60 n = 6294,   1.32 ±  0.63 0.971 
Total stent length (mm) n = 25090,  27.76 ± 17.36 n = 18799,  27.98 ± 17.40 n = 6291,  27.09 ± 17.20 0.001 
Mean stent diameter (mm) n = 25089,   2.94 ±  0.59 n = 18798,   2.97 ±  0.62 n = 6291,   2.87 ±  0.46 <0.001 
Treatment of a bifurcation n = 27031,  3750 (13.9%) n = 20330,  2827 (13.9%) n = 6701,   923 (13.8%) 0.543 
Baseline TIMI flow n = 26607, n = 20021, n = 6586, 0.002 
0 or 1 6239 (23.4%) 4834 (24.1%) 1405 (21.3%)   
2 4210 (15.8%) 3136 (15.7%) 1074 (16.3%)   
3 16157 (60.7%) 12050 (60.2%) 4107 (62.4%)   
Post TIMI flow n = 26727, n = 20115, n = 6612, 0.606 
0 or 1 184  (0.7%) 137  (0.7%) 47  (0.7%)   
2 387  (1.4%) 298  (1.5%) 89  (1.3%)   
3 26156 (97.9%) 19680 (97.8%) 6476 (97.9%)   
 
DES= drug eluting stent; IABP= intra-aortic balloon pump; PCI= percutaneous coronary intervention 














Table S3. Medications in male and female patients. 
  All patients Male Female p-value 
  N = 16821 N = 12514 N = 4307   
Procedure medications, no.(%)         
Loading procedure n = 16821, n = 12514, n = 4307, <0.001 
No loading dose 1387  (8.2%) 1020  (8.2%) 367  (8.5%) 0.441 
Only loading Clopidogrel 8060 (47.9%) 5818 (46.5%) 2242 (52.1%) <0.001 
Only loading Prasugrel 1908 (11.3%) 1564 (12.5%) 344  (8.0%) <0.001 
Only loading Ticagrelor 4605 (27.4%) 3409 (27.2%) 1196 (27.8%) 0.513 
Loading Clopidogrel and Prasugrel 681  (4.0%) 571  (4.6%) 110  (2.6%) <0.001 
Loading Clopidogrel and Ticagrelor 154  (0.9%) 109  (0.9%) 45  (1.0%) 0.308 
Loading Prasugrel and Ticagrelor 26  (0.2%) 23  (0.2%) 3  (0.1%) 0.117 
Unfract. Heparin n = 16808, 16452 (97.9%) n = 12507, 12244 (97.9%) n = 4301, 4208 (97.8%) 0.806 
Fondaparinux n = 15460,  1685 (10.9%) n = 11501,  1231 (10.7%) n = 3959,  454 (11.5%) 0.183 
LMWH n = 16803,   307  (1.8%) n = 12502,   223  (1.8%) n = 4301,   84  (2.0%) 0.468 
Bivalirudin n = 16803,   302  (1.8%) n = 12502,   236  (1.9%) n = 4301,   66  (1.5%) 0.143 
Glycoprotein IIb/IIIa inhibitors n = 16807,  1497  (8.9%) n = 12506,  1202  (9.6%) n = 4301,  295  (6.9%) <0.001 
Thrombolytic therapy n = 15455,    48  (0.3%) n = 11498,    35  (0.3%) n = 3957,   13  (0.3%) 0.868 
Discharge medications, no.(%)         
Aspirin n = 16415, 15881 (96.7%) n = 12215, 11834 (96.9%) n = 4200, 4047 (96.4%) 0.107 
Clopidogrel n = 16415,  8850 (53.9%) n = 12215,  6380 (52.2%) n = 4200, 2470 (58.8%) <0.001 
Prasugrel n = 16415,  2721 (16.6%) n = 12215,  2232 (18.3%) n = 4200,  489 (11.6%) <0.001 
Ticagrelor n = 16415,  4539 (27.7%) n = 12215,  3376 (27.6%) n = 4200, 1163 (27.7%) 0.952 
Any DAPT n = 16415, 15623 (95.2%) n = 12215, 11639 (95.3%) n = 4200, 3984 (94.9%) 0.278 
Any OAC n = 16412,  1943 (11.8%) n = 12214,  1460 (12.0%) n = 4198,  483 (11.5%) 0.455 
Novel oral anticoagulants n = 11600,   689  (5.9%) n =  8630,   515  (6.0%) n = 2970,  174  (5.9%) 0.857 
Any DAPT and OAC/NOAC n = 16412,  1655 (10.1%) n = 12214,  1266 (10.4%) n = 4198,  389  (9.3%) 0.043 
Statin n = 16412, 14924 (90.9%) n = 12214, 11264 (92.2%) n = 4198, 3660 (87.2%) <0.001 
PPI n = 12425,  5036 (40.5%) n =  9294,  3567 (38.4%) n = 3131, 1469 (46.9%) <0.001 
One year follow-up medications, no.(%)         








Clopidogrel* n = 14356,  5378 (37.5%) n = 10753,  3865 (35.9%) n = 3603, 1513 (42.0%) <0.001 
Prasugrel* n = 14356,  2069 (14.4%) n = 10753,  1705 (15.9%) n = 3603,  364 (10.1%) <0.001 
Ticagrelor* n = 14355,  2951 (20.6%) n = 10752,  2262 (21.0%) n = 3603,  689 (19.1%) 0.014 
Any DAPT* n = 14355,  9365 (65.2%) n = 10752,  7059 (65.7%) n = 3603, 2306 (64.0%) 0.072 
Any OAC n = 14338,  1971 (13.7%) n = 10743,  1466 (13.6%) n = 3595,  505 (14.0%) 0.557 
Novel oral anticoagulants n = 11336,   836  (7.4%) n =  8492,   621  (7.3%) n = 2844,  215  (7.6%) 0.679 
Any DAPT and OAC/NOAC n = 14339,   250  (1.7%) n = 10743,   190  (1.8%) n = 3596,   60  (1.7%) 0.768 
Statin n = 14337, 12042 (84.0%) n = 10742,  9225 (85.9%) n = 3595, 2817 (78.4%) <0.001 
PPI n = 11741,  3993 (34.0%) n =  8825,  2831 (32.1%) n = 2916, 1162 (39.8%) <0.001 
          
*not stopped before 350 days since index PCI considered compliant. 


















Hazard ratio  
[95% CI] 
p-value 
Bleeding BARC (2) 322 (2.8) 95 (2.5)  0.87 (0.69-1.10) 0.237 
access site 6 (0.1) 7 (0.2)  3.42 (1.15-10.17) 0.027 
non-access site 317 (2.8) 89 (2.3)  0.83 (0.65-1.05) 0.116 
Bleeding BARC (3a) 188 (1.6) 95 (2.4)  1.50 (1.17-1.92) 0.001 
access site 23 (0.2) 22 (0.5)  2.81 (1.57-5.04) <0.001 
non-access site 168 (1.5) 75 (1.9)  1.32 (1.01-1.74) 0.044 
Bleeding BARC (3b) 214 (1.9) 94 (2.4)  1.30 (1.02-1.65) 0.035 
access site 24 (0.2) 21 (0.5)  2.57 (1.43-4.62) 0.002 
non-access site 192 (1.7) 73 (1.8)  1.12 (0.86-1.47) 0.402 
Bleeding BARC (3c) 46 (0.4) 22 (0.6)  1.41 (0.85-2.35) 0.181 
Bleeding BARC (5ab) 33 (0.3) 21 (0.5)  1.87 (1.08-3.24) 0.024 
access site 0 (0.0) 1 (0.0)  8.72 (0.36-214.01)* 0.256 
non-access site 33 (0.3) 20 (0.5)  1.79 (1.02-3.11) 0.041 
Bleeding GUSTO (severe or moderate) 419 (3.6) 203 (5.1)   1.44 (1.22-1.71) <0.001 
access site 39 (0.3) 34 (0.8)   2.56 (1.62-4.06) <0.001 
non-access site 385 (3.4) 172 (4.4)   1.33 (1.11-1.59) 0.002 
Bleeding GUSTO (severe) 227 (2.0) 118 (3.0)   1.54 (1.23-1.92) <0.001 
access site 14 (0.1) 12 (0.3)   2.51 (1.16-5.43) 0.019 
non-access site 215 (1.9) 107 (2.7)   1.47 (1.17-1.86) 0.001 
Bleeding GUSTO (moderate) 210 (1.8) 98 (2.5)   1.38 (1.09-1.76) 0.008 
access site 25 (0.2) 22 (0.5)   2.59 (1.46-4.59) 0.001 
non-access site 186 (1.6) 77 (2.0)   1.23 (0.94-1.60) 0.131 
Bleeding GUSTO (mild) 379 (3.3) 116 (3.0)   0.90 (0.73-1.11) 0.337 
access site 15 (0.1) 19 (0.5)   3.72 (1.89-7.32) <0.001 
non-access site 366 (3.2) 99 (2.6)   0.80 (0.64-0.99) 0.045 
Bleeding TIMI (major or minor) 437 (3.8) 199 (5.0)   1.35 (1.14-1.60) <0.001 
access site 45 (0.4) 42 (1.0)   2.75 (1.80-4.18) <0.001 








Bleeding TIMI (major) 267 (2.3) 114 (2.9)   1.26 (1.01-1.57) 0.037 
access site 21 (0.2) 14 (0.3)   1.96 (0.99-3.85) 0.052 
non-access site 249 (2.2) 101 (2.6)   1.20 (0.95-1.51) 0.124 
Bleeding TIMI (minor) 184 (1.6) 94 (2.4)   1.51 (1.18-1.94) 0.001 
access site 24 (0.2) 28 (0.7)   3.43 (1.99-5.92) <0.001 
non-access site 164 (1.4) 67 (1.7)   1.21 (0.91-1.61) 0.191 
Bleeding TIMI (minimal) 356 (3.1) 120 (3.1)   1.00 (0.81-1.22) 0.970 
access site 8 (0.1) 11 (0.3)   4.03 (1.62-10.03) 0.003 
non-access site 348 (3.1) 110 (2.9)   0.93 (0.75-1.16) 0.525 
 

















 events/patients: 593/16821 
ACCESS-SITE 
events/patients: 91/16821 
 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Female sex 1.41 (1.15-1.73) 0.001 1.25 (1.02-1.54) 0.035 2.76 (1.65-4.60) <0.001 
Age (years) 1.03 (1.02-1.04) <0.001 1.03 (1.02-1.05) <0.001 1.04 (1.02-1.06) 0.001 
BMI 0.95 (0.94-0.97) <0.001 0.95 (0.93-0.97) <0.001 0.96 (0.91-1.01) 0.087 
Current smoker 0.77 (0.64-0.92) 0.004 0.84 (0.70-1.02) 0.074 0.33 (0.20-0.55) <0.001 
Diabetes mellitus 1.11 (0.86-1.44) 0.431 1.10 (0.85-1.44) 0.463 1.13 (0.70-1.83) 0.609 
Hypertension 1.20 (0.96-1.52) 0.116 1.23 (0.97-1.56) 0.094 1.09 (0.60-1.98) 0.777 
Hypercholesterolemia 0.83 (0.72-0.94) 0.004 0.81 (0.71-0.93) 0.004 0.81 (0.58-1.13) 0.220 
Family history of coronary artery disease 0.77 (0.67-0.89) <0.001 0.75 (0.62-0.90) 0.003 0.92 (0.66-1.27) 0.594 
Previous myocardial infarction 1.11 (0.89-1.38) 0.360 1.13 (0.91-1.40) 0.254 0.84 (0.52-1.36) 0.483 
Previous PCls 0.93 (0.78-1.10) 0.404 0.96 (0.79-1.17) 0.709 0.63 (0.39-1.00) 0.049 
Previous CABG 1.00 (0.80-1.24) 0.987 1.10 (0.87-1.40) 0.430 0.30 (0.11-0.86) 0.026 
History of Cerebrovascular Accident 1.55 (1.13-2.13) 0.007 1.49 (1.10-2.01) 0.010 1.76 (0.83-3.74) 0.139 
Peripheral arterial disease 1.51 (1.20-1.89) <0.001 1.58 (1.25-2.00) <0.001 1.17 (0.55-2.48) 0.681 
History of malignancy 1.58 (1.22-2.03) <0.001 1.66 (1.25-2.20) <0.001 0.92 (0.58-1.45) 0.719 
Renal failure [MDRD] 2.57 (2.23-2.98) <0.001 2.61 (2.17-3.14) <0.001 2.40 (1.39-4.13) 0.002 
History of atrial fibrillation/atrial flutter 2.47 (2.01-3.05) <0.001 2.48 (2.02-3.05) <0.001 2.17 (1.44-3.28) <0.001 
Chronic obstructive lung disease 1.64 (1.21-2.21) 0.001 1.71 (1.21-2.42) 0.002 1.36 (0.75-2.47) 0.306 
History of spontaneous bleeding 2.49 (1.89-3.28) <0.001 2.49 (1.89-3.27) <0.001 2.46 (1.38-4.38) 0.002 
Hemoglobin before PCI (g/L) 0.97 (0.97-0.98) <0.001 0.97 (0.97-0.98) <0.001 0.97 (0.96-0.98) <0.001 
Left ventricular function (%) 0.97 (0.97-0.98) <0.001 0.97 (0.97-0.98) <0.001 0.97 (0.96-0.99) 0.005 
Killip II, III or IV 2.92 (2.66-3.19) <0.001 3.02 (2.75-3.32) <0.001 2.51 (1.42-4.42) 0.001 
Unstable Angina* 0.81 (0.51-1.27) 0.358 0.70 (0.42-1.17) 0.173 1.43 (0.68-3.02) 0.344 
NSTEMI* 1.16 (0.97-1.39) 0.103 1.17 (0.99-1.38) 0.069 1.09 (0.71-1.67) 0.700 
STEMI* 1.35 (1.10-1.67) 0.004 1.38 (1.07-1.78) 0.012 1.13 (0.63-2.01) 0.684 
Femoral access† 1.00 (0.71-1.43) 0.983 0.94 (0.65-1.36) 0.727 1.73 (0.95-3.15) 0.075 
IABP 2.92 (1.81-4.72) <0.001 2.65 (1.44-4.89) 0.002 4.08 (1.50-11.09) 0.006 
Percutaneous left ventricular assist device 9.35 (7.31-11.96) <0.001 8.43 (6.00-11.85) <0.001 12.34 (5.77-26.41) <0.001 








Total stent length (mm) ‡ 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.02) 0.265 
Left anterior descending artery 0.85 (0.77-0.93) <0.001 0.81 (0.70-0.94) 0.005 1.31 (0.75-2.29) 0.345 
Restenotic lesion 0.96 (0.72-1.28) 0.799 1.04 (0.76-1.42) 0.822 0.42 (0.13-1.30) 0.131 
Evidence of thrombus 1.27 (1.05-1.53) 0.012 1.33 (1.08-1.63) 0.007 0.85 (0.46-1.57) 0.599 
Chronic total occlusion 1.13 (0.80-1.61) 0.48 1.18 (0.84-1.66) 0.334 0.96 (0.32-2.87) 0.935 
Discharge: Triple therapy DAPT + OAC§ 1.84 (1.62-2.10) <0.001 1.78 (1.49-2.13) <0.001 2.26 (1.38-3.70) 0.001 
Discharge: Any OAC§ 1.95 (1.62-2.35) <0.001 1.89 (1.53-2.35) <0.001 2.44 (1.55-3.82) <0.001 
Discharge: Any DAPT§ 0.65 (0.44-0.96) 0.029 0.67 (0.46-0.97) 0.036 0.52 (0.23-1.18) 0.117 
Discharge: Prasugrel or Ticagrelor DAPT§ 0.75 (0.57-1.01) 0.056 0.75 (0.56-1.01) 0.061 0.71 (0.50-1.01) 0.057 
Discharge: PPI, not at follow-up|| 2.18 (1.62-2.92) <0.001 2.23 (1.61-3.08) <0.001 1.99 (1.28-3.09) 0.002 
Follow-up: PPI, not at discharge|| 1.97 (1.46-2.66) <0.001 2.16 (1.55-3.01) <0.001 0.80 (0.44-1.45) 0.465 
Discharge and follow-up: PPI|| 1.33 (1.02-1.74) 0.032 1.32 (1.01-1.72) 0.039 1.38 (0.81-2.35) 0.239 
Staged PCI 0.82 (0.64-1.06) 0.126 0.81 (0.59-1.11) 0.186 0.83 (0.51-1.34) 0.437 
Staged PCI Femoral access 1.15 (0.81-1.62) 0.432 1.11 (0.76-1.63) 0.580 1.24 (0.62-2.48) 0.548 
Cluster robustified estimates by the year of PCI (2009-2018).  
*Stable CAD patients are the reference category; †Patients with PCI in 2009, 2010, 2011 all femoral access; ‡Stent length zero for ballooning only; §OAC and DAPT at discharge, if 
deceased in-hospital: as used at procedure; ||No PPI is the reference category 
 
BMI= Body mass Index; CABG= coronary artery bypass graft; DAPT= dual antiplatelet therapy; HR= Hazard Ratio; IABP= intra-aortic balloon pump; NOAC new oral anticoagulant; 




























Female sex 1.01 (0.81-1.27) 0.918 0.88 (0.72-1.09) 0.244 2.14 (1.22-3.74) 0.008 
Age at date of informed consent 1.01 (1.00-1.02) 0.019 1.01 (1.00-1.02) 0.049 - - 
BMI 0.97 (0.95-0.99) 0.001 0.96 (0.94-0.98) <0.001 - - 
Current smoker - - - - 0.40 (0.24-0.66) <0.001 
Renal failure [MDRD] 1.38 (1.18-1.62) <0.001 1.43 (1.18-1.73) <0.001 - - 
History of atrial fibrillation/atrial flutter 1.64 (1.28-2.09) <0.001 1.66 (1.32-2.07) <0.001 - - 
Previous PCls - - - - 0.58 (0.35-0.93) 0.025 
Previous CABG - - 0.80 (0.59-1.09) 0.163 -  
Chronic obstructive lung disease 1.30 (0.98-1.73) 0.074 1.31 (0.94-1.83) 0.113 - - 
History of spontaneous bleeding 1.37 (1.02-1.83) 0.038 1.37 (1.02-1.85) 0.037 1.92 (1.03-3.55) 0.039 
Hemoglobin before PCI (g/L) 0.99 (0.98-0.99) <0.001 0.99 (0.98-0.99) <0.001 0.99 (0.97-1.00) 0.034 
Killip II, III or IV 1.68 (1.49-1.90) <0.001 1.76 (1.54-2.01) <0.001 1.73 (1.04-2.90) 0.036 
Unstable Angina* 1.10 (0.65-1.87) 0.719 0.58 (0.40-0.84) 0.004 - - 
NSTEMI* 1.20 (0.89-1.62) 0.242 0.55 (0.27-1.12) 0.098 - - 
STEMI* 1.81 (1.30-2.53) <0.001 0.68 (0.51-0.89) 0.006 - - 
Percutaneous left ventricular assist device 5.49 (4.09-7.35) <0.001 4.77 (3.12-7.31) <0.001 8.32 (4.11-16.84) <0.001 
IABP (prior or during PCI) - - - - 2.08 (0.86-5.04) 0.106 
Left anterior descending artery - - 0.83 (0.72-0.96) 0.010 - - 
Total stent length (mm)*** 1.01 (1.00-1.01) 0.002 1.01 (1.00-1.01) 0.002 - - 
Discharge: Any DAPT 0.73 (0.54-0.99) 0.043 - - 0.50 (0.24-1.07) 0.074 
Discharge: potent P2Y12 inhibitor DAPT 0.79 (0.57-1.10) 0.165 0.76 (0.53-1.09) 0.132 - - 
Discharge: Any DAPT and OAC/NOAC - - - - 2.11 (1.36-3.28) <0.001 
Discharge: PPI, not at follow-up** 2.06 (1.41-3.00) <0.001 2.16 (1.39-3.35) <0.001 - - 
Follow-up: PPI, not at discharge** 2.42 (1.71-3.41) <0.001 2.64 (1.79-3.91) <0.001 - - 
Discharge and follow-up: PPI** 1.48 (1.10-1.99) 0.010 1.51 (1.07-2.13) 0.020 - - 
Staged PCI 0.65 (0.46-0.91) 0.012 - - - - 
Femoral access site at Staged PCI 1.53 (1.09-2.15) 0.014 - - - - 
 
Cluster robustified estimates by the year of PCI (2009-2018).  
*Stable CAD patients are the reference category; †Stent length zero for ballooning only; ‡OAC and DAPT at discharge, if deceased in-hospital: as used at procedure; §No PPI is the 
reference category. 
BMI= Body mass Index; CABG= coronary artery bypass graft; DAPT= dual antiplatelet therapy; HR= Hazard Ratio; IABP= intra-aortic balloon pump; NOAC new oral anticoagulant; 

















 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Female sex 1.22 (1.03-1.43) 0.020 1.08 (0.91-1.28) 0.368 2.83 (1.83-4.39) <0.001 
Age (years) 1.03 (1.03-1.04) <0.001 1.03 (1.03-1.04) <0.001 1.04 (1.02-1.06) <0.001 
BMI 0.97 (0.96-0.98) <0.001 0.97 (0.95-0.98) <0.001 0.96 (0.91-1.00) 0.066 
Current smoker 0.75 (0.66-0.86) <0.001 0.80 (0.69-0.92) 0.003 0.39 (0.25-0.60) <0.001 
Diabetes mellitus 1.16 (0.97-1.39) 0.105 1.15 (0.96-1.38) 0.117 1.17 (0.64-2.14) 0.599 
Hypertension 1.20 (1.05-1.37) 0.006 1.22 (1.08-1.38) 0.001 1.03 (0.60-1.76) 0.918 
Hypercholesterolemia 0.80 (0.71-0.91) <0.001 0.79 (0.70-0.90) <0.001 0.79 (0.57-1.08) 0.140 
Family history of coronary artery disease 0.69 (0.61-0.79) <0.001 0.67 (0.58-0.78) <0.001 0.86 (0.58-1.28) 0.458 
Previous myocardial infarction 1.10 (0.88-1.38) 0.414 1.13 (0.91-1.40) 0.283 0.78 (0.43-1.41) 0.412 
Previous PCls 0.94 (0.80-1.10) 0.436 0.94 (0.80-1.11) 0.470 0.76 (0.45-1.28) 0.296 
Previous CABG 0.99 (0.84-1.16) 0.890 1.05 (0.90-1.23) 0.537 0.35 (0.14-0.87) 0.023 
History of Cerebrovascular Accident 1.47 (1.13-1.90) 0.004 1.43 (1.10-1.87) 0.007 1.52 (0.75-3.05) 0.243 
Peripheral arterial disease 1.46 (1.24-1.73) <0.001 1.54 (1.29-1.84) <0.001 1.01 (0.45-2.29) 0.981 
History of malignancy 1.65 (1.38-1.97) <0.001 1.71 (1.41-2.08) <0.001 0.99 (0.65-1.50) 0.966 
Renal failure [MDRD] 2.32 (1.98-2.72) <0.001 2.35 (1.95-2.84) <0.001 2.32 (1.50-3.58) <0.001 
History of atrial fibrillation/atrial flutter 2.17 (1.81-2.60) <0.001 2.16 (1.83-2.55) <0.001 2.15 (1.43-3.22) <0.001 
Chronic obstructive lung disease 1.59 (1.24-2.03) <0.001 1.63 (1.24-2.14) <0.001 1.34 (0.80-2.24) 0.263 
History of spontaneous bleeding 2.41 (2.05-2.84) <0.001 2.46 (2.12-2.85) <0.001 2.12 (1.12-4.01) 0.021 
Hemoglobin before PCI (g/L) 0.98 (0.97-0.98) <0.001 0.98 (0.97-0.98) <0.001 0.97 (0.97-0.98) <0.001 
Left ventricular function (%) 0.98 (0.97-0.98) <0.001 0.98 (0.97-0.98) <0.001 0.98 (0.96-0.99) 0.011 
Killip II, III or IV 2.58 (2.34-2.85) <0.001 2.63 (2.37-2.92) <0.001 2.38 (1.35-4.19) 0.003 
Unstable Angina* 0.97 (0.73-1.29) 0.850 0.93 (0.69-1.25) 0.613 1.47 (0.68-3.14) 0.325 
NSTEMI* 1.19 (1.01-1.41) 0.040 1.21 (1.02-1.43) 0.029 1.06 (0.73-1.55) 0.746 
STEMI* 1.36 (1.21-1.53) <0.001 1.36 (1.19-1.56) <0.001 1.31 (0.74-2.33) 0.357 
Femoral access† 0.90 (0.65-1.24) 0.511 0.85 (0.60-1.21) 0.368 1.73 (1.08-2.77) 0.023 
IABP 2.43 (1.49-3.96) <0.001 2.34 (1.31-4.16) 0.004 3.54 (1.26-9.92) 0.016 
Percutaneous left ventricular assist device 7.41 (5.42-10.12) <0.001 6.84 (4.88-9.59) <0.001 10.64 (4.94-22.89) <0.001 
Number of lesions 0.98 (0.90-1.08) 0.741 0.96 (0.87-1.07) 0.454 1.23 (1.01-1.50) 0.039 
Total stent length (mm) ‡ 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.02) 0.162 
Left anterior descending artery 0.86 (0.76-0.99) 0.032 0.84 (0.72-0.99) 0.038 1.28 (0.73-2.25) 0.389 
Restenotic lesion 0.95 (0.81-1.13) 0.577 0.99 (0.84-1.18) 0.946 0.48 (0.19-1.24) 0.129 
Evidence of thrombus 1.29 (1.13-1.47) <0.001 1.30 (1.14-1.49) <0.001 1.05 (0.62-1.77) 0.86 








Discharge: Triple therapy DAPT + OAC§ 1.88 (1.67-2.12) <0.001 1.83 (1.59-2.10) <0.001 2.18 (1.38-3.43) <0.001 
Discharge: Any OAC§ 1.89 (1.67-2.13) <0.001 1.84 (1.61-2.09) <0.001 2.29 (1.47-3.58) <0.001 
Discharge: Any DAPT§ 0.87 (0.60-1.27) 0.470 0.91 (0.64-1.30) 0.615 0.60 (0.26-1.39) 0.233 
Discharge: Prasugrel or Ticagrelor DAPT§ 0.90 (0.69-1.18) 0.441 0.91 (0.69-1.19) 0.481 0.80 (0.57-1.11) 0.175 
Discharge: PPI, not at follow-up|| 2.24 (1.70-2.94) <0.001 2.29 (1.69-3.11) <0.001 1.88 (1.24-2.85) 0.003 
Follow-up: PPI, not at discharge|| 1.79 (1.35-2.38) <0.001 1.86 (1.36-2.54) <0.001 1.21 (0.58-2.51) 0.610 
Discharge and follow-up: PPI|| 1.42 (1.06-1.90) 0.019 1.41 (1.04-1.91) 0.026 1.47 (0.98-2.21) 0.062 
Staged PCI 1.01 (0.86-1.20) 0.872 1.02 (0.84-1.23) 0.876 0.90 (0.52-1.55) 0.710 
Staged PCI Femoral access 1.32 (0.97-1.81) 0.079 1.31 (0.93-1.85) 0.128 1.22 (0.58-2.57) 0.606 
 
Cluster robustified estimates by the year of PCI (2009-2018).  
*Stable CAD patients are the reference category; †Patients with PCI in 2009, 2010, 2011 all femoral access; ‡Stent length zero for ballooning only; §OAC and DAPT at discharge, if 
deceased in-hospital: as used at procedure; ||No PPI is the reference category 
BMI= Body mass Index; CABG= coronary artery bypass graft; DAPT= dual antiplatelet therapy; HR= Hazard Ratio; IABP= intra-aortic balloon pump; NOAC new oral anticoagulant; 

















 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Female sex 0.89 (0.74-1.06) 0.195 0.78 (0.65-0.94) 0.008 2.15 (1.34-3.43) 0.001 
Age at date of informed consent 1.02 (1.01-1.02) <0.001 1.02 (1.01-1.03) <0.001 - - 
BMI 0.98 (0.97-0.99) 0.004 0.98 (0.97-0.99) 0.007 - - 
Hypercholesterolemia  - - 0.91 (0.79-1.04) 0.169 - - 
Current smoker - -  - - 0.47 (0.30-0.73) <0.001 
Previous CABG 0.73 (0.61-0.88) <0.001 0.79 (0.63-0.99) 0.039 0.30 (0.12-0.71) 0.007 
History of malignancy 1.24 (1.03-1.49) 0.022 1.28 (1.05-1.55) 0.014 - - 
Renal failure [MDRD] 1.31 (1.13-1.52) <0.001 1.34 (1.11-1.63) 0.003 - - 
History of atrial fibrillation/atrial flutter 1.55 (1.26-1.90) <0.001 1.52 (1.27-1.82) <0.001 - - 
Chronic obstructive lung disease 1.25 (0.99-1.58) 0.058 1.26 (0.97-1.63) 0.084 - - 
History of spontaneous bleeding 1.43 (1.18-1.72) <0.001 1.43 (1.19-1.73) <0.001 1.65 (0.84-3.26) 0.149 
Hemoglobin before PCI (g/L) 0.99 (0.98-0.99) <0.001 0.99 (0.98-0.99) <0.001 0.98 (0.97-1.00) 0.007 
Left ventricular function (%) 0.99 (0.99-1.00) 0.039 0.99 (0.99-1.00) 0.057 - - 
Killip II, III or IV 1.49 (1.33-1.68) <0.001 1.52 (1.32-1.75) <0.001 1.70 (1.03-2.79) 0.036 
Unstable Angina* 1.31 (0.91-1.87) 0.144 1.24 (0.84-1.83) 0.289 - - 
NSTEMI* 1.17 (0.97-1.40) 0.094 1.17 (0.96-1.43) 0.112 - - 
STEMI* 1.58 (1.36-1.83) <0.001 1.54 (1.30-1.82) <0.001 - - 
Percutaneous left ventricular assist device 4.32 (2.89-6.46) <0.001 3.79 (2.41-5.97) <0.001 7.63 (3.59-16.22) <0.001 
Left anterior descending artery 0.86 (0.75-0.98) 0.020 0.86 (0.74-1.01) 0.070 - - 
Chronic total occlusion 1.31 (0.97-1.76) 0.081 1.36 (1.02-1.80) 0.034 - - 
Total stent length (mm)† 1.00 (1.00-1.01) 0.012 1.01 (1.00-1.01) 0.003 - - 
Number of lesions - - 0.91 (0.83-1.00) 0.062 1.20 (0.98-1.46) 0.070 
Discharge: Any OAC‡ - - - - 2.09 (1.32-3.28) 0.001 
Discharge: PPI, not at follow-up§ 2.15 (1.57-2.92) <0.001 2.19 (1.56-3.08) <0.001 - - 
Follow-up: PPI, not at discharge§ 2.18 (1.62-2.93) <0.001 2.27 (1.64-3.14) <0.001 - - 
Discharge and follow-up: PPI§ 1.55 (1.16-2.08) 0.003 1.57 (1.15-2.14) 0.005 - - 
 
Cluster robustified estimates by the year of PCI (2009-2018).  
*Stable CAD patients are the reference category; †Stent length zero for ballooning only; ‡OAC and DAPT at discharge, if deceased in-hospital: as used at procedure; §No PPI is the 
reference category 
BMI= Body mass Index; CABG= coronary artery bypass graft; DAPT= dual antiplatelet therapy; HR= Hazard Ratio; IABP= intra-aortic balloon pump; NOAC new oral anticoagulant; 








Table S9. Contemporary studies reporting a sex-related adjusted risk for bleeding after PCI at a longer follow up (>6 months). 
Author (year of 
publication) 











Adjusted bleeding risk increased 
in females 






Anderson et al. 
(2012) 
22988009 
Cath-PCI Registry and 
Medicare 
Obs. PCI ≥65y 675460 2004 - 2008 Study specific 30 months N Y Y 
Berry et al. (2018) 30354781 DAPT RCT PCI 25682 2009 - 2011 GUSTO moderate/severe  1 year Y - N 
Chandiramani et al. 
(2020) 
32223396 
4 post-approval Xience 
studies 
Obs. 
HBR patients and PCI 
with XIENCE V stent 
2397 - 
TIMI minor/major or 
GUSTO moderate/severe 
4 years N N - 
Chandrasekhar et al.   
(2017) 
27152497 Prometheus Obs. PCI and ACS <55years 4851 2010 - 2013 Study specific 1 year N - - 
Clemmensen et al. 
(2015) 
26386793 TRILOGY ACS  RCT ACS without PCI 9326 2008 - 2011 
GUSTO moderate/severe 
and TIMI minor/major 
30 months N‡ - - 
D'Ascenzo et al. 
(2018) 
30228021 RENAMI  Obs. ACS and PCI 4424 2013 - 2015 BARC 3 or 5 
14.1 ± 6.2 
months 
Y - - 
Gargiulo et al. (2016) 27544007 PRODIGY RCT PCI 1970 2006 - 2008 
BARC 2,3 or 5, TIMI 
minor/major, GUSTO 
moderate/severe 
2 years N - - 
Grodecki et al. (2018) 30064688 BleeMACS Obs. PCI  and ACS 13727 2003 - 2014 Study specific 1 year N   
Hess et al. (2014) 24510115 
TRANSLATE-ACS  
 
RCT PCI and ACS 6218 2010 - 2012 
GUSTO mild/moderate/ 
severe and BARC 1-5 
1 year Y - - 
Hochholzer et al. 
(2011) 
21606391 TRITON-TIMI 38 RCT PCI and ACS 13420 2004 - 2007 
TIMI minor/major with 
transfusion 
15 months Y - - 
Husted et al. (2014) 24682844 PLATO RCT PCI and ACS 18624 2006 - 2008 Study specific and TIMI 240 days N Y - 
Ko et al. (2010) 20332382 
Regional Registry 
(Ontario, Canada) 
Obs. PCI >65y 22798 2003 - 2007 Study specific 1 year N‡ - - 
Mehran et al. (2020) 32432718 LEADERS-FREE  RCT PCI and HBR 2432 2012 - 2014 BARC 2, 3 or 5 2 years N Y Y 
Nakamura et al. (2019) 31748446 PRASFIT-Practice II Obs. 
ACS and PCI treated 
with prasugrel 
4155 2015 - 2018 TIMI minor/major 1 year N Y - 
Shin et al. (2014) 24793670 Korean TCI Registry Obs. PCI with radial access 1194 2009 - 2009 Study specific 1 year Y - - 
Xanthopoulou et al. 
(2017) 
28459500 GRAPE Registry Obs. 
PCI moderate to high 
risk 
2049 2012 - 2013 BARC 1-5 1 year Y - - 
Xu et al. (2018) 29490431 
Single-centre registry 
(Beijing, China) 
Obs. PCI patients >60y 10724 2013 - 2013 BARC 1-5 2 years Y - - 
Yu J et al. (2015) 25115966 HORIZONS-AMI RCT PCI and STEMI 3602 2005 - 2007 Study specific 3 years Y - - 
Sawaya et al. (2017) 27426936 
IPD Meta-analysis of 6 
RCT*  
  11473  TIMI and BARC  N - - 
Lau et al. (2017) 28335837 Meta-analysis†   87840  TIMI minor/major  N - - 








* RCT included: EXCELLENT, OPTIMIZE, PRODIGY, RESET, SECURITY, ITALIC PLUS 
† RCT included: TRITON-TIMI, PLATO, CHAMPION PCI, CHAMPION PLATFORM, TRILOGY-ACS, CHAMPION PHOENIX, PEGASUS-TIMI 54;  










Figure S1. BARC 3 or 5 bleeding at 1 year: crude rates, unadjusted and adjusted Hazard Risks (HR) in males and females in whose a 









Figure S2. Prevalence of minor and *major ARC-HBR criteria (A) and distribution of ARC-HBR score (B) in males (blue) and females 






















































CKD=Chronic Kidney Disease; NSAIDs= non-steroidal anti-inflammatory drugs; PCI= percutaneous coronary intervention 








Figure S4. Non access-site (A) and access-site (B) BARC 3 or 5 bleeding incidence at 1 year for ARC-






 http://ahajournals.org by on Septem
ber 29, 2021
